Cancer Res (2026) 86 (5_Supplement_2): A010.
Cancer Immunol Res (2026) 14 (2_Supplement): B024.
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts. 3Harvard Medical School, ...
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Search for other works by this author on: School of Pharmacy, Faculty of Medicine, The Chinese ...
Mol Cancer Ther (2025) 24 (10_Supplement): A045.
You do not currently have access to this content.
Cancer Res (2025) 85 (8_Supplement_2): ND11.
Hanmi Pharmaceutical Co., Ltd., Hwaseong-si, Republic of Korea.
Cyclin E (CCNE1) is amplified in multiple cancers including approximately 10% of esophagogastric cancers and 20% of ovarian cancers. CCNE1 amplification leads to DNA replication stress and chromosomal ...
Abstract. Molecular glue degrader (MGD) is an emerging therapeutic strategy offering an exciting alternative to traditional small molecules exploring new target space. These small molecules interact ...
Ubix Therapeutics Co., Ltd., Seoul, Republic of Korea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results